<p>Cognition Therapeutics, Inc.（纳斯达克代码：CGTX - 获取免费报告）的股票在覆盖该股票的五家券商中获得了 “适度买入” 的共识评级，MarketBeat.com 报道。一位研究分析师给予该股票卖出评级，三位给予买入评级，一位给予强烈买入评级。在过去一年中，发布报告的分析师对该股票的平均十二个月目标价格为 $3.3333。</p>
<ul>
<li>十一月的小型股宝藏：三只有望增长的股票</li>
</ul>
<p>CGTX 已成为多份研究报告的主题。B. Riley 在周五的研究报告中重申了 “买入” 评级，并将 Cognition Therapeutics 的目标价格设定为 $3.00（上调自 $2.00）。华尔街 Zen 在 11 月 8 日的研究报告中将 Cognition Therapeutics 的股票评级从 “卖出” 上调至 “持有”。Weiss Ratings 在周二的报告中重申了对 Cognition Therapeutics 股票的 “卖出（d-）” 评级。Chardan Capital 在 8 月 8 日的研究报告中重新发布了 “买入” 评级，并将 Cognition Therapeutics 的目标价格设定为 $4.00。最后，HC Wainwright 在周三的研究报告中重申了 “买入” 评级，并对 Cognition Therapeutics 的股票设定了 $3.00 的目标价格。</p>
<p>获取 <strong>Cognition Therapeutics</strong> 的提醒：</p>
<p><strong>查看我们最新的 Cognition Therapeutics 股票分析</strong></p>
<h2>Cognition Therapeutics 股票上涨 4.5%</h2>
<p>CGTX 股票在周五上涨 $0.06，达到 $1.39。该公司股票的交易量为 916,768 股，而其平均交易量为 1,075,655 股。Cognition Therapeutics 的十二个月低点为 $0.22，十二个月高点为 $3.83。该股票的 50 日移动平均线为 $1.60，200 日移动平均线为 $1.15。该公司的市值为 $1.227 亿，市盈率为 -2.90，贝塔值为 1.23。</p>
<p>Cognition Therapeutics（纳斯达克代码：CGTX - 获取免费报告）最近于 11 月 6 日发布了其财报。该公司报告本季度每股收益为 ($0.06)，超出市场共识预期的 ($0.07) $0.01。平均而言，股票研究分析师预测 Cognition Therapeutics 本财年的每股收益为 -0.8。</p>
<h2>Cognition Therapeutics 的机构交易</h2>
<p>一些大型投资者最近对 CGTX 的持仓进行了调整。DAVENPORT &amp; Co LLC 在第三季度购买了 Cognition Therapeutics 的新股份，价值约 $3,631,000。Vanguard Group Inc. 在第三季度将其在 Cognition Therapeutics 的持股增加了 105.6%。Vanguard Group Inc. 现在拥有 2,681,613 股该公司的股票，价值 $3,620,000，此前在此期间又收购了 1,377,263 股。Acadian Asset Management LLC 在第一季度将其在 Cognition Therapeutics 的持股增加了 814.1%。Acadian Asset Management LLC 现在拥有 1,007,586 股该公司的股票，价值 $422,000，此前在上个季度又收购了 897,353 股。Chescapmanager LLC 在第三季度将其在 Cognition Therapeutics 的持股增加了 98.1%。Chescapmanager LLC 现在拥有 997,029 股该公司的股票，价值 $1,346,000，此前在此期间又购买了 493,770 股。最后，Millennium Management LLC 在第三季度收购了 Cognition Therapeutics 的新股份，价值 $757,000。机构投资者和对冲基金持有该公司 43.35% 的股票。</p>
<h2>关于 Cognition Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Cognition Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于发现和开发针对与年龄相关的退行性疾病以及中枢神经系统和视网膜疾病的小分子治疗药物。其主要产品候选药物是 CT1812，这是一种口服给药的分子调节剂，旨在穿透血脑屏障并选择性结合 S2R 复合体，目前正在进行阿尔茨海默病的二期临床试验，以及针对干性年龄相关性黄斑变性和路易体痴呆等突触蛋白病的地理萎缩的治疗。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Cognition Therapeutics</li>
<li>三只天然气股票，提供优厚的股息收益</li>
<li>MP Materials 股票在财报后飙升——真正原因在这里</li>
<li>为什么投资高收益股息股票？</li>
<li>为什么 Palantir 的下滑可能是长期机会的铺垫</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>收入投资者注意：这只 REIT 正在打折出售</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Cognition Therapeutics 吗？</h2>
<p>在考虑投资 Cognition Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cognition Therapeutics 并不在名单上。</p>
<p>虽然 Cognition Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CGTX

<p>Cognition Therapeutics, Inc.（纳斯达克代码：CGTX）获得了五家券商的 “适度买入” 共识评级。该股票有一个卖出评级、三个买入评级和一个强力买入评级。平均十二个月目标价为 3.3333 美元。最近的评级包括 B. Riley 的买入评级，目标价为 3.00 美元，以及 Chardan Capital 的买入评级，目标价为 4.00 美元。该股票目前交易价格为 1.39 美元。机构投资者持有该公司 43.35% 的股份</p>

<p>Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have been given a consensus rating of &#34;Moderate Buy&#34; by the five brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $3.3333.</p>
<div class="lb-trans"><p>Cognition Therapeutics, Inc.（纳斯达克代码：CGTX - 获取免费报告）的股票在覆盖该股票的五家券商中获得了 “适度买入” 的共识评级，MarketBeat.com 报道。一位研究分析师给予该股票卖出评级，三位给予买入评级，一位给予强烈买入评级。在过去一年中，发布报告的分析师对该股票的平均十二个月目标价格为 $3.3333。</p>
</div><ul>
<li>November’s Small-Cap Treasures: 3 Stocks Poised for Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>十一月的小型股宝藏：三只有望增长的股票</li>
</ul>
</div><p>CGTX has been the subject of a number of research reports. B. Riley reiterated a &#34;buy&#34; rating and set a $3.00 price target (up from $2.00) on shares of Cognition Therapeutics in a research report on Friday. Wall Street Zen raised shares of Cognition Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Cognition Therapeutics in a report on Tuesday. Chardan Capital reissued a &#34;buy&#34; rating and set a $4.00 price objective on shares of Cognition Therapeutics in a research note on Friday, August 8th. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $3.00 target price on shares of Cognition Therapeutics in a research note on Wednesday.</p>
<div class="lb-trans"><p>CGTX 已成为多份研究报告的主题。B. Riley 在周五的研究报告中重申了 “买入” 评级，并将 Cognition Therapeutics 的目标价格设定为 $3.00（上调自 $2.00）。华尔街 Zen 在 11 月 8 日的研究报告中将 Cognition Therapeutics 的股票评级从 “卖出” 上调至 “持有”。Weiss Ratings 在周二的报告中重申了对 Cognition Therapeutics 股票的 “卖出（d-）” 评级。Chardan Capital 在 8 月 8 日的研究报告中重新发布了 “买入” 评级，并将 Cognition Therapeutics 的目标价格设定为 $4.00。最后，HC Wainwright 在周三的研究报告中重申了 “买入” 评级，并对 Cognition Therapeutics 的股票设定了 $3.00 的目标价格。</p>
</div><p>Get <strong>Cognition Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cognition Therapeutics</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Cognition Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Cognition Therapeutics 股票分析</strong></p>
</div><h2>Cognition Therapeutics Stock Up 4.5%</h2>
<div class="lb-trans"><h2>Cognition Therapeutics 股票上涨 4.5%</h2>
</div><p>CGTX stock traded up $0.06 on Friday, reaching $1.39. 916,768 shares of the company's stock were exchanged, compared to its average volume of 1,075,655. Cognition Therapeutics has a twelve month low of $0.22 and a twelve month high of $3.83. The stock has a fifty day moving average of $1.60 and a 200-day moving average of $1.15. The firm has a market cap of $122.70 million, a PE ratio of -2.90 and a beta of 1.23.</p>
<div class="lb-trans"><p>CGTX 股票在周五上涨 $0.06，达到 $1.39。该公司股票的交易量为 916,768 股，而其平均交易量为 1,075,655 股。Cognition Therapeutics 的十二个月低点为 $0.22，十二个月高点为 $3.83。该股票的 50 日移动平均线为 $1.60，200 日移动平均线为 $1.15。该公司的市值为 $1.227 亿，市盈率为 -2.90，贝塔值为 1.23。</p>
</div><p>Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. On average, equities research analysts predict that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cognition Therapeutics（纳斯达克代码：CGTX - 获取免费报告）最近于 11 月 6 日发布了其财报。该公司报告本季度每股收益为 ($0.06)，超出市场共识预期的 ($0.07) $0.01。平均而言，股票研究分析师预测 Cognition Therapeutics 本财年的每股收益为 -0.8。</p>
</div><h2>Institutional Trading of Cognition Therapeutics</h2>
<div class="lb-trans"><h2>Cognition Therapeutics 的机构交易</h2>
</div><p>A number of large investors have recently made changes to their positions in CGTX. DAVENPORT &amp; Co LLC purchased a new stake in shares of Cognition Therapeutics during the third quarter worth about $3,631,000. Vanguard Group Inc. grew its stake in Cognition Therapeutics by 105.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company's stock worth $3,620,000 after acquiring an additional 1,377,263 shares during the period. Acadian Asset Management LLC raised its holdings in Cognition Therapeutics by 814.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company's stock valued at $422,000 after acquiring an additional 897,353 shares during the last quarter. Chescapmanager LLC lifted its stake in shares of Cognition Therapeutics by 98.1% during the 3rd quarter. Chescapmanager LLC now owns 997,029 shares of the company's stock worth $1,346,000 after purchasing an additional 493,770 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Cognition Therapeutics during the third quarter worth $757,000. Institutional investors and hedge funds own 43.35% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近对 CGTX 的持仓进行了调整。DAVENPORT &amp; Co LLC 在第三季度购买了 Cognition Therapeutics 的新股份，价值约 $3,631,000。Vanguard Group Inc. 在第三季度将其在 Cognition Therapeutics 的持股增加了 105.6%。Vanguard Group Inc. 现在拥有 2,681,613 股该公司的股票，价值 $3,620,000，此前在此期间又收购了 1,377,263 股。Acadian Asset Management LLC 在第一季度将其在 Cognition Therapeutics 的持股增加了 814.1%。Acadian Asset Management LLC 现在拥有 1,007,586 股该公司的股票，价值 $422,000，此前在上个季度又收购了 897,353 股。Chescapmanager LLC 在第三季度将其在 Cognition Therapeutics 的持股增加了 98.1%。Chescapmanager LLC 现在拥有 997,029 股该公司的股票，价值 $1,346,000，此前在此期间又购买了 493,770 股。最后，Millennium Management LLC 在第三季度收购了 Cognition Therapeutics 的新股份，价值 $757,000。机构投资者和对冲基金持有该公司 43.35% 的股票。</p>
</div><h2>About Cognition Therapeutics</h2>
<div class="lb-trans"><h2>关于 Cognition Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.</p>
<div class="lb-trans"><p>Cognition Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于发现和开发针对与年龄相关的退行性疾病以及中枢神经系统和视网膜疾病的小分子治疗药物。其主要产品候选药物是 CT1812，这是一种口服给药的分子调节剂，旨在穿透血脑屏障并选择性结合 S2R 复合体，目前正在进行阿尔茨海默病的二期临床试验，以及针对干性年龄相关性黄斑变性和路易体痴呆等突触蛋白病的地理萎缩的治疗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Cognition Therapeutics</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>MP Materials Stock Soared After Earnings—Here’s the Real Reason</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>Why Palantir Slide May Be a Setup for a Long-Term Opportunity</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>Attention Income Investors: This REIT Is on Sale</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Cognition Therapeutics</li>
<li>三只天然气股票，提供优厚的股息收益</li>
<li>MP Materials 股票在财报后飙升——真正原因在这里</li>
<li>为什么投资高收益股息股票？</li>
<li>为什么 Palantir 的下滑可能是长期机会的铺垫</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>收入投资者注意：这只 REIT 正在打折出售</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CGTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cognition Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Cognition Therapeutics 吗？</h2>
</div><p>Before you consider Cognition Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Cognition Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognition Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cognition Therapeutics 并不在名单上。</p>
</div><p>While Cognition Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cognition Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cognition Therapeutics, Inc.（纳斯达克股票代码：CGTX）被分析师一致推荐为 “适度买入”